Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

Cure My Disease

Don't miss your cure!

 Log in / Sign up

Can a heart Pump's data predict who will recover?

NCT ID NCT07619144

Knowledge-focused Sponsor: Medical University of Vienna Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now This study
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This study looks at data from 100 adults with cardiogenic shock who received an Impella 5.5 heart pump. Researchers aim to build a tool that uses pump signals to predict whether a patient's own heart will recover. The goal is to improve decision-making and reduce complications like bleeding or organ failure.

What this could mean

Our plain-language read of the trial. This is informational only, not medical advice or a prediction.

Active substance
Impella 5.5 micro-axial flow pump (a temporary heart pump device)
What this could lead to
If successful, this could lead to a tool that helps doctors predict which patients will recover their own heart function, potentially reducing deaths and complications.
What could go wrong
This is a small, early-stage observational study, not a treatment trial. The tool may not prove accurate enough for real-world use, and results may not apply to all patients.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Participants

About 100 people

The number the study aims to enrol. It can still change while the study runs.

Started

May 2026

Expected to finish

May 2029

An estimate. End dates often move.

Lead sponsor

Other sponsor

The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Who is studied

The study population comprises adult patients admitted to the intensive care unit (ICU) presenting with severe cardiogenic shock who required temporary mechanical circulatory support between January 2019 and March 2026, treated at the Medical University of Vienna, Austria. Eligible individuals are those who undergo clinical management utilizing the Impella 5.5 micro-axial flow pump as part of their standard of care. Only patients with available high-resolution pump data (downloaded from the clinical console) and ICU digital health record datasets extracted from ICCA (IntelliSpace Critical Care and Anesthesia, Philips Medical Systems Development and Manufacturing Centre, Hamburg, Germany) will be included for analysis.

Ages

18 years and older

Sex

Anyone

Healthy volunteers

Not accepted

This study is not open to healthy volunteers. The entry requirements below say who it is open to.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: * Adult patients who were treated for cardiogenic shock and supported with an Impella 5.5 micro-axial flow pump * Only patients with available high-resolution pump data (downloaded from the clinical console) and ICU digital health record datasets Exclusion Criteria: * Patients supported with an Impella 5.5 for indications other than cardiogenic shock (e.g., protected PCI or CABG) * Patients younger than 18 years * Patients with incomplete data, procedural records, or demographic information

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Cardiogenic shock are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Conditions

The condition(s) this trial relates to.

cardiogenic shock Shock, Cardiogenic

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Cardiogenic shock Cardiogenic shock post myocardial infarction Mechanical circulatory support

How to take part

Only the study team decides who joins. These are the ways to reach them.

  1. The places running it

    1 site. The list below names each one and where it is.

  2. The official record

    ClinicalTrials.gov lists the study team's own contact details, including names and phone numbers. We don't republish those.

    Open the record ↗

  3. A doctor treating you

    A doctor who knows your case can contact a study site on your behalf, and can tell you whether this study is worth pursuing at all.

Contacts and locations

Locations

  • Medical University of Vienna

    RECRUITING

    Vienna, Austria

More trials for these conditions

Other studies related to the condition(s) this trial covers.